ENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a Prescription
Rhea-AI Summary
ENvue Medical (NASDAQ: FEED) announced on January 14, 2026 the launch of over-the-counter ENFit syringes for enteral feeding and medication delivery, available without a prescription. The syringes will be sold in institutional and consumer-friendly packaging and are anticipated to appear at certain online retailers including Amazon and durable medical equipment suppliers. Offered in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, the devices comply with ISO 80369-3 and are designed for reuse for up to seven days or 20 uses, aiming to support continuity of care across clinical and home settings.
Positive
- OTC availability via Amazon and DME suppliers
- Meets ISO 80369-3 global enteral connector standard
- Reusable for up to seven days or 20 uses
- Offered in 2.5, 5, 10, and 60 mL sizes
Negative
- None.
News Market Reaction – FEED
On the day this news was published, FEED declined 26.72%, reflecting a significant negative market reaction. Argus tracked a peak move of +26.7% during that session. Argus tracked a trough of -43.6% from its starting point during tracking. Our momentum scanner triggered 48 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $921K from the company's valuation, bringing the market cap to $3M at that time. Trading volume was exceptionally heavy at 62.6x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers in the specified sector showed momentum flags; the 1.75% pre-news gain looks stock-specific rather than part of a broader sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Clinical program launch | Positive | -7.6% | Exploratory program using NanoVibronix vibration tech for NG tube discomfort. |
| Jan 08 | Nasdaq bell ceremony | Positive | +11.1% | Nasdaq Opening Bell event highlighting enteral and non-opioid pain focus. |
| Dec 15 | Leadership change | Positive | -5.6% | Appointment of experienced healthcare executive as Chairman and expansion plans. |
Recent news often drew mixed-to-negative immediate reactions, with two of three largely positive updates followed by price declines.
Over the last month, ENvue Medical issued three notable updates. On Dec 15, 2025, it appointed David Johnson as Chairman and highlighted use of its 510(k) FDA-cleared system in 38 U.S. hospitals, yet shares fell 5.61%. A Nasdaq Opening Bell announcement on Jan 8, 2026 coincided with an 11.11% gain. A clinical program update on Jan 9, 2026 then saw shares decline 7.6%. Today’s OTC ENFit syringe launch extends the focus on enteral-care solutions into home and retail channels.
Market Pulse Summary
The stock dropped -26.7% in the session following this news. A negative reaction despite a commercial product launch would fit prior instances where largely constructive updates were followed by weakness. The OTC ENFit syringes expand ENvue’s enteral-delivery offerings into retail and home settings, but past news, including leadership changes and clinical initiatives, sometimes preceded declines. Traders might weigh execution risk, existing reliance on a niche hospital base, and overall liquidity when assessing whether selling pressure could overshoot fundamentals.
Key Terms
enteral medical
enfit syringes medical
durable medical equipment technical
iso 80369-3 technical
AI-generated analysis. Not financial advice.
New Product Line Enhances Continuity of Care Across Clinical and Home Settings
TYLER, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a line of over-the-counter ENFit Syringes designed to meet both feeding and medication delivery clinical needs.
“As care continues to shift beyond the hospital setting, providers and caregivers need reliable, high-quality solutions that support patients throughout the entire care journey,” said Doron Besser, MD, CEO of ENvue Medical. “With the launch of our over-the-counter ENFit Syringes, available in institutional and consumer-friendly packaging, we are expanding access to safe, affordable and standardized enteral delivery tools that support patients, caregivers, and clinicians wherever care is delivered—while remaining aligned with our mission to improve patient experiences and outcomes.”
ENvue’s ENFit Syringes are currently anticipated to be available at certain online retailers including Amazon and Durable Medical Equipment suppliers in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, without the need for a prescription. The ENFit syringes meet ISO 80369-3 global standards and are designed for reuse for up to seven days or 20 uses, helping support safe and consistent enteral delivery in both clinical and home care environments.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, the availability of ENFit Syringes, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Raquel Cona, Vice President
PH: (516) 779-2630
envue@kcsa.com
FAQ
When did ENvue Medical (FEED) announce the over-the-counter ENFit syringes?
Which retailers will carry ENvue ENFit syringes for FEED shareholders?
What ENFit syringe sizes did ENvue (FEED) launch for OTC sale?
Do ENvue ENFit syringes meet international standards (FEED)?
How long can the new ENvue ENFit syringes be reused according to the announcement?
What is the primary purpose of ENvue's OTC ENFit syringe launch for FEED investors?
